Oxazepam (Serax)

03/01/1982 - "Oxazepam is recommended in alcoholic cirrhotics because its plasma clearance does not seem to be significantly affected by liver disease. "
03/01/1981 - "Usual ranges for kinetic parameters are: elimination half-life, 5 to 15 hours; volume of distribution, 0.6 to 2.0 L/kg; clearance, 0.9 to 2.0 ml/min/kg. Age and liver disease have a minimal influence on oxazepam kinetics, but renal disease is associated with a prolonged half-life and increased volume of distribution. "
11/01/1978 - "Oxazepam disposition is unaffected by age and liver disease. "
11/01/1968 - "[The autonomic stabilization of patients with liver diseases using Adumbran]."
04/01/1976 - "Unlike many other sedatives, oxazepam is eliminated normally in patients with parenchymal liver disease an therefore, on pharmacokinetic grounds, seems to be an excellent sedative for use in such persons."

02/01/1984 - "Oxazepam produced some rebound insomnia, consisting of about an hour's reduction of polysomnographically defined sleep, but without gross mood disturbance or the patients' awareness of sleep loss."
08/01/1978 - "It is concluded that oxazepam is safe and efficacious for the short-term management of insomnia in the elderly."
02/01/1984 - "Nighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia."
01/01/1983 - "In a multicentre, double-blind, parallel study performed in 78 hospitalized patients who complained of mild, moderate or severe insomnia, the efficacy and safety of 15 mg midazolam were compared with those of 15 mg oxazepam, both orally administered. "
11/25/2002 - "Patients aged 18 to 73 years and diagnosed with non-organic insomnia according to ICD-10 (F 51.0) were treated in a multicentre, double-blind, randomised parallel group comparison with either 600 mg/die valerian extract LI 156 (Sedonium) or 10 mg/die oxazepam taken for 6 weeks. "

06/01/1985 - "Relief of chronic intractable hallucinosis in residual schizophrenia with oxazepam."
01/01/2023 - "Retracted: Efficacy of Risperidone Orally Disintegrating Tablets Combined with Oxazepam in the Treatment of Schizophrenia."
01/01/2022 - "To explore the efficacy of risperidone orally disintegrating tablets combined with oxazepam in the treatment of schizophrenia. "
01/01/2022 - "Efficacy of Risperidone Orally Disintegrating Tablets Combined with Oxazepam in the Treatment of Schizophrenia."
01/01/2022 - "Risperidone orally disintegrating tablets combined with oxazepam shows potential in the treatment of schizophrenia by relieving patients' mental symptoms, improving quality of life and activities of daily living, and minimizing the incidence of adverse reactions."

03/01/2017 - "However, oxazepam specifically inhibited neither emotional mimicry nor empathy for pain. "
03/01/2017 - "First, we aimed to investigate the effects of oxazepam on emotional mimicry and empathy for pain, and second, we aimed to investigate the association of personality traits to emotional mimicry and empathy. "
03/01/2017 - "Effects of 25 mg oxazepam on emotional mimicry and empathy for pain: a randomized controlled experiment."
01/01/2022 - "This study aimed to compare the efficacy of gabapentin and oxazepam on sleep quality, the severity of anxiety, and pain level in patients admitted to the coronary care unit (CCU). "
01/01/1987 - "Morphine effects on activity and pain reactivity of developing mice with or without late prenatal oxazepam exposure."

08/01/1993 - "Average daily oxazepam consumption varied throughout the studies, and the overall daily average ranged from 10 to 29 mg/kg body weight for the 125 ppm groups, 234 to 512 mg/kg for the 2,500 ppm groups, and 444 to 1,085 mg/kg for the 5,000 ppm groups. "
10/01/1998 - "The continuous-exposure concentrations resulted in average daily doses of 25, 100, or 250 mg oxazepam/kg body weight to males and 25, 110, or 220 mg/kg to females. "
01/01/1994 - "Few effects were observed resulting from chronic exposure to oxazepam other than statistically significant, dose-related increases in liver/body weight ratios. "
01/01/1994 - "Male B6C3F1 mice (10 per dose-time group) received diets containing oxazepam at 0, 25, 125, 2500, and 5000 ppm. Mice were treated for 15, 30, 45, or 90 days, at which time they were evaluated for feed consumption, liver/body weight ratios, clinical pathology, serum oxazepam levels, and histopathology of the liver. "
08/01/1993 - "Dietary levels of 125, 2,500, and 5,000 ppm resulted in average daily oxazepam consumption levels of 12, 310, and 690 mg/kg body weight for males and 15, 350, and 780 mg/kg for females. "